Interaction Between Coronavirus S-Protein and Human ACE2: Hints for Exploring Efficient Therapeutic Targets to Treat COVID-19
- PMID: 32864982
- DOI: 10.1177/0003319720952284
Interaction Between Coronavirus S-Protein and Human ACE2: Hints for Exploring Efficient Therapeutic Targets to Treat COVID-19
Abstract
With the global expansion of coronavirus disease 2019 (COVID-19) and the declaration of its outbreak as a Public Health Emergency of International Concern by the World Health Organization, there is an urgent need for vaccines and medicines to prevent and treat COVID-19. The responsible pathogen for the disease is the newly severe acute respiratory syndrome coronavirus (SARS-CoV) 2 belonging to the same family of viruses SARS-CoV and Middle East respiratory syndrome coronavirus that originally are zoonotic and have been associated with severe illness during the outbreaks in 2003 and 2012, respectively. The virulence of coronavirus strains is mainly associated with variations in surface proteins mediating cellular entry of the virus, which can help in finding effective therapeutic targets. In this review, we seek evidence showing the role of coronavirus spike protein (S-protein) and its potential cellular receptor, angiotensin-converting enzyme 2 (ACE2), during infection of coronaviruses, including the newly SARS-CoV-2 and its similar strain SARS-CoV. This review also discusses the therapeutic effect of inhibiting the renin-angiotensin system cascade, a target of ACE2, in patients having coronavirus with cardiovascular disease.
Keywords: COVID-19; angiotensin-converting enzyme 2; coronavirus; renin-angiotensin system; spike protein.
Similar articles
-
The expression of hACE2 receptor protein and its involvement in SARS-CoV-2 entry, pathogenesis, and its application as potential therapeutic target.Tumour Biol. 2021;43(1):177-196. doi: 10.3233/TUB-200084. Tumour Biol. 2021. PMID: 34420993 Review.
-
Angiotensin-Converting Enzyme 2 (ACE2) in the Pathogenesis of ARDS in COVID-19.Front Immunol. 2021 Dec 22;12:732690. doi: 10.3389/fimmu.2021.732690. eCollection 2021. Front Immunol. 2021. PMID: 35003058 Free PMC article. Review.
-
Killing Two Birds with One Stone by Administration of Soluble ACE2: A Promising Strategy to Treat Both Cardiovascular Diseases and SARS-CoV-2 Infection.Viruses. 2021 Nov 8;13(11):2243. doi: 10.3390/v13112243. Viruses. 2021. PMID: 34835049 Free PMC article. Review.
-
Epigallocatechin gallate (EGCG) attenuates severe acute respiratory coronavirus disease 2 (SARS-CoV-2) infection by blocking the interaction of SARS-CoV-2 spike protein receptor-binding domain to human angiotensin-converting enzyme 2.PLoS One. 2022 Jul 13;17(7):e0271112. doi: 10.1371/journal.pone.0271112. eCollection 2022. PLoS One. 2022. PMID: 35830431 Free PMC article.
-
Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.Trials. 2021 Jan 11;22(1):42. doi: 10.1186/s13063-020-04998-5. Trials. 2021. PMID: 33430924 Free PMC article.
Cited by
-
Acute Coronary Syndrome in the COVID-19 Era-Differences and Dilemmas Compared to the Pre-COVID-19 Era.J Clin Med. 2022 May 27;11(11):3024. doi: 10.3390/jcm11113024. J Clin Med. 2022. PMID: 35683411 Free PMC article. Review.
-
[Activation of endoplasmic reticulum stress sensors by metabolic disease-associated diets and COVID-19].Rev Med Inst Mex Seguro Soc. 2022 Mar 1;60(2):211-223. Rev Med Inst Mex Seguro Soc. 2022. PMID: 35759643 Free PMC article. Review. Spanish.
-
Specific Activation of T Cells by an ACE2-Based CAR-Like Receptor upon Recognition of SARS-CoV-2 Spike Protein.Int J Mol Sci. 2023 Apr 21;24(8):7641. doi: 10.3390/ijms24087641. Int J Mol Sci. 2023. PMID: 37108807 Free PMC article.
-
From Cell to Symptoms: The Role of SARS-CoV-2 Cytopathic Effects in the Pathogenesis of COVID-19 and Long COVID.Int J Mol Sci. 2023 May 5;24(9):8290. doi: 10.3390/ijms24098290. Int J Mol Sci. 2023. PMID: 37175995 Free PMC article. Review.
-
Statin Use in COVID-19 Hospitalized Patients and Outcomes: A Retrospective Study.Front Cardiovasc Med. 2022 Feb 24;9:820260. doi: 10.3389/fcvm.2022.820260. eCollection 2022. Front Cardiovasc Med. 2022. PMID: 35282379 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous